Study to Evaluate Safety and Immunogenicity of the GSK Bio CMV Vaccine in CMV-seronegative Healthy Male Adult Subjects

Inclusion Criteria: * Subjects who the investigator believes that they can and will comply with the requirements of the protocol should be enrolled in the study. * Male between, and including, 18 and 40 years of age at the time of the first vaccination. * Written informed consent obtained from the subject. * The subject consents to being informed of his CMV and HSV serostatus. * Healthy subjects as established by medical history and clinical examination before entering into the study. * Seronegative for CMV. * Previously completed routine childhood vaccinations to the best of his knowledge. Exclusion Criteria: * The HSV serologic status. * Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period. * Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose. * Any chronic drug therapy to be continued during the study period. * Receipt of live attenuated vaccines within 30 days of study vaccine administration. * Receipt of medically indicated subunit or killed vaccines (e.g., influenza, pneumococcal) or allergy treatment with antigen injections within 14 days of study vaccine administration. * Prior receipt of the adjuvant or any of its components being used in this study. * Previous vaccination against CMV. * History of recurrent herpes simplex infection (more than 1 episode per year). * Any confirmed or suspected immunosuppressive or immunodeficient condition * Hepatitis B infection or hepatitis C infection. * A family history of congenital or hereditary immunodeficiency. * History of allergic disease or reactions likely to be exacerbated by any component of the vaccine. * Major congenital defects or serious chronic illness including but not limited to diabetes mellitus and thyroid disease * History of any neurologic disorders or seizures except people with febrile convulsions before the age of 5. * History of malignancy * Acute disease at the time of enrollment. * Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination or laboratory screening tests. * Hepatomegaly, right upper quadrant abdominal pain or tenderness. * Decreased renal function * Administration of immunoglobulins and/or any blood products within the three months preceding the first dose of study vaccine or planned administration during the study period. * History of chronic alcohol consumption and/or drug abuse.